World's Best Scientists 2026 revealed!
Ian J. Stratford

Ian J. Stratford

D-Index & Metrics

Chemistry

D-Index
68
Citations
14742
World Ranking
6617
National Ranking
161

Biology and Biochemistry

D-Index
81
Citations
24468
World Ranking
3880
National Ranking
92

Overview

Ian J. Stratford is affiliated with RMIT University in Australia. Their research primarily focuses on biochemistry, genetics, molecular biology, chemistry, pharmacology, toxicology, and pharmaceutics. The scientific work spans several subfields, including organic chemistry, molecular biology, toxicology, cancer research, and surgery.

The scientist's recent papers demonstrate involvement in various topics related to bioactive compounds and antitumor agents, synthesis and biological activity, cancer, hypoxia, metabolism, RNA interference and gene delivery, pancreatic function and diabetes, synthesis and biological evaluation, as well as genomics, phytochemicals, and oxidative stress. Key topics of their work include:

  • Bioactive Compounds and Antitumor Agents
  • Synthesis and biological activity
  • Cancer, Hypoxia, and Metabolism
  • RNA Interference and Gene Delivery
  • Pancreatic function and diabetes
  • Synthesis and Biological Evaluation
  • Genomics, phytochemicals, and oxidative stress

Their notable recent publications cover various aspects of medicinal chemistry and molecular sciences. Selected papers include:

  • SAR of Novel 3-Arylisoquinolinones: meta-Substitution on the Aryl Ring Dramatically Enhances Antiproliferative Activity through Binding to Microtubules, 2022, Journal of Medicinal Chemistry
  • Targeting Hypoxia-Inducible Factor-1α in Pancreatic Cancer: siRNA Delivery Using Hyaluronic Acid-Displaying Nanoparticles, 2024, Pharmaceutics
  • Discovery of Potent Benzothiazole Inhibitors of Oxidoreductase NQO2, a Target for Inflammation and Cancer, 2024, International Journal of Molecular Sciences

The publication venues where Ian J. Stratford frequently contributes include:

  • Pharmaceutics
  • Journal of Medicinal Chemistry
  • International Journal of Molecular Sciences

Collaborations have been established with several researchers across multiple projects, including:

  • Annalisa Tirella
  • Asma A. Belgath
  • Richard A. Bryce
  • Sally Freeman
  • Alice Spadea

Best Publications

  • Guidelines for the welfare and use of animals in cancer research

    P Workman;E O Aboagye;F Balkwill;A Balmain

  • Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.

    P H Maxwell;G U Dachs;J M Gleadle;L G Nicholls

  • Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

    Simon J. Dovedi;Amy L. Adlard;Grazyna Lipowska-Bhalla;Conor McKenna

  • Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix.

    Juliette A. Loncaster;Adrian L. Harris;Susan E. Davidson;John P. Logue

  • Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361

    Christopher R. Calabrese;Robert Almassy;Stephanie Barton;Michael A. Batey

  • Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance.

    Janine T Erler;Christopher Cawthorne;Kaye J Williams;Marianne Koritzinsky

  • Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers.

    G. E. Adams;I. R. Flockhart;C. E. Smithen;I. J. Stratford

  • Targeting gene expression to hypoxic tumor cells.

    G.U Dachs;Aa.V Patterson;Aa.V Patterson;J.D Firth;P.J Ratcliffe

  • Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix.

    R Airley;Juliette A Loncaster;Susan E Davidson;Michael Bromley

  • Clinical development of new drug-radiotherapy combinations

    Ricky A Sharma;Ruth Plummer;Julie K Stock;Tessa A Greenhalgh

  • Structure-activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency

    G.E. Adams;E.D. Clarke;I.R. Flockhart;R.S. Jacobs

  • Targeting gene therapy to cancer: a review.

    G U Dachs;G J Dougherty;I J Stratford;D J Chaplin

  • GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding.

    Rachel E. Airley;Juliette Loncaster;James A. Raleigh;Adrian L. Harris

  • HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.

    P J Maxwell;R Gallagher;A Seaton;C Wilson

  • The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo.

    Leigh Griffiths;Gabi U. Dachs;Roy Bicknell;Adrian L. Harris

  • Site and strain-specific variation in gut microbiota profiles and metabolism in experimental mice.

    Melissa K. Friswell;Helen Gika;Helen Gika;Ian J. Stratford;Georgios Theodoridis;Georgios Theodoridis

  • ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.

    Kaye J. Williams;B. A. Telfer;I. J. Stratford;S. R. Wedge

  • Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix.

    Rachel A Cooper;Bernadette M Carrington;Juliette A Loncaster;Susan M Todd

  • Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.

    Jonathan D. Silk;Ian F. Hermans;Uzi Gileadi;Tsung Wen Chong

  • Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft

    Joana M. Senra;Brian A Telfer;Kim E Cherry;Cian M McCrudden

  • Radiation sensitization and chemopotentiation: Rsu 1069, a compound more efficient than misonidazole in vitro and in vivo

    G E Adams;I Ahmed;P W Sheldon;I J Stratford

Frequent Co-Authors

adrian l harris
adrian l harris University of Oxford
Catharine M L West
Catharine M L West University of Manchester
Kenneth T. Douglas
Kenneth T. Douglas University of Manchester
Nicola Tirelli
Nicola Tirelli Italian Institute of Technology
Caroline Dive
Caroline Dive University of Manchester
Peter J. Ratcliffe
Peter J. Ratcliffe The Francis Crick Institute
Robin G. Pritchard
Robin G. Pritchard University of Manchester
Christopher W. Pugh
Christopher W. Pugh University of Oxford
Paul Workman
Paul Workman Institute of Cancer Research
Christopher J. Moody
Christopher J. Moody University of Nottingham

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Ian J. Stratford

Trending Scientists